Back to AMPE Stock Lookup

Ampio Pharma (AMPE) – Press Releases

Sep 2, 2014 07:56 AM Update on the Phase III multicenter, double-blind STEP study of Ampion™ for Osteoarthritis of the Knee
Aug 25, 2014 07:56 AM Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion™ BLA
Aug 21, 2014 07:56 AM Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed
Aug 20, 2014 07:56 AM Analysis Of Available Data From Optimeyes Study (Blinded And Open Label) Of Optina™ For The Treatment Of Diabetic Macular Edema (DME) Indicates Potential For Significant Clinical Benefit
Aug 19, 2014 07:56 AM Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meetin
Aug 18, 2014 08:00 AM Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial
Aug 11, 2014 08:00 AM Luoxis Broadens Global Research Network for RedoxSYS™ oxidation-reduction potential (ORP) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014
Aug 5, 2014 08:00 AM Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee.
Jul 30, 2014 08:00 AM Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility.
Jul 23, 2014 08:00 AM Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
Jun 30, 2014 08:00 AM Ampio Initiates Study of Multiple Injections of Ampion™ Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects
Jun 25, 2014 08:00 AM Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (Optina™) and Will Present the Data to the FDA for Guidance
Jun 5, 2014 08:00 AM Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer

Back to AMPE Stock Lookup